Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rhys Whomsley

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Theranostics|July 26, 2017
Vandetanib-eluting Radiopaque Beads: <i>In vivo</i> Pharmacokinetics, Safety and Toxicity Evaluation following Swine Liver EmbolizationAlban Denys, Peter Czuczman, David Grey, et al.
Frontiers in Medicine|December 6, 2021
The EU Response to the Presence of Nitrosamine Impurities in MedicinesRobin Ruepp, Roland Frötschl, Robert Bream, et al.
ALTEX|June 26, 2025
Estimation of bioavailable concentration of endogenously formed N-nitrosamines by physiologically based kinetic modellingMax Spaenig, Matthias Vogel, Tanja Hansen, et al.
Drug Metabolism Reviews|July 16, 2009
Drug metabolism and pharmacokineticsMargherita Strolin Benedetti, Rhys Whomsley, Italo Poggesi, et al.
Environment International|December 28, 2023
Prioritisation of data-poor pharmaceuticals for empirical testing and environmental risk assessmentCristiana Cannata, Thomas Backhaus, Irene Bramke, et al.
Radiology|October 17, 2019
Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver CancerRafael Duran, Julien Namur, Florentina Pascale, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 29, 2003
Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytesFrancoise de Longueville, Franck A Atienzar, Laurence Marcq, et al.
British Journal of Clinical Pharmacology|June 2, 2023
EMA commentary on the ICH guideline for testing for carcinogenicity of pharmaceuticalsJan Willem van der Laan, Mikael Andersson, Sonja Beken, et al.
Integrated Environmental Assessment and Management|May 5, 2026
A framework to Identify High-Priority Legacy Active Pharmaceutical Ingredients for Environmental Risk AssessmentCristiana Cannata, Erika Colombo, Ashenafi Legehar, et al.
Mutagenesis|February 14, 2026
Nitrosamine Ames Data Review and Method Development: Proceedings of a US FDA/HESI WorkshopAisar Atrakchi, Raechel Puglisi, Joel Bercu, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Theranostics|July 26, 2017
Vandetanib-eluting Radiopaque Beads: <i>In vivo</i> Pharmacokinetics, Safety and Toxicity Evaluation following Swine Liver EmbolizationAlban Denys, Peter Czuczman, David Grey, et al.
Frontiers in Medicine|December 6, 2021
The EU Response to the Presence of Nitrosamine Impurities in MedicinesRobin Ruepp, Roland Frötschl, Robert Bream, et al.
ALTEX|June 26, 2025
Estimation of bioavailable concentration of endogenously formed N-nitrosamines by physiologically based kinetic modellingMax Spaenig, Matthias Vogel, Tanja Hansen, et al.
Drug Metabolism Reviews|July 16, 2009
Drug metabolism and pharmacokineticsMargherita Strolin Benedetti, Rhys Whomsley, Italo Poggesi, et al.
Environment International|December 28, 2023
Prioritisation of data-poor pharmaceuticals for empirical testing and environmental risk assessmentCristiana Cannata, Thomas Backhaus, Irene Bramke, et al.
Radiology|October 17, 2019
Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver CancerRafael Duran, Julien Namur, Florentina Pascale, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 29, 2003
Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytesFrancoise de Longueville, Franck A Atienzar, Laurence Marcq, et al.
British Journal of Clinical Pharmacology|June 2, 2023
EMA commentary on the ICH guideline for testing for carcinogenicity of pharmaceuticalsJan Willem van der Laan, Mikael Andersson, Sonja Beken, et al.
Integrated Environmental Assessment and Management|May 5, 2026
A framework to Identify High-Priority Legacy Active Pharmaceutical Ingredients for Environmental Risk AssessmentCristiana Cannata, Erika Colombo, Ashenafi Legehar, et al.
Mutagenesis|February 14, 2026
Nitrosamine Ames Data Review and Method Development: Proceedings of a US FDA/HESI WorkshopAisar Atrakchi, Raechel Puglisi, Joel Bercu, et al.
Pageof 3